Phase 2 N=61 Study of Pharmacology of 17-OHPC in Pregnancy
Pregnancy
Primary: Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy. — 115; 136 ng/ML/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
N/A N=38 Clinical Pharmacology of Electronic Cigarettes
Nicotine Dependence
Primary: Standardized Session: Mean CMax — 6.1; 20.2 ng/mL
Phase 1 N=9 Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 1719 ng·h/mL
N/A N=107 Pharmacokinetics of Daunorubicin in Young Patients With Cancer
Unspecified Childhood Solid Tumor, Protocol Specific
Primary: Population Estimates for Daunorubicin Hydrochloride Clearance — 116 L/m2/hr
Phase 4 N=105 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
Phase 1 N=6 Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 2300 ng·h/mL
Phase 4 N=44 Conditioned Pharmacotherapeutic Effects in Hypertension
Hypertension
Primary: Mean Systolic Blood Pressure — 151.59; 152.64; 155.42; 151.74 mmHg
N/A N=190 Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
Pharmacogenetics
Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
Early Phase 1 N=6 Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
N/A N=21 Pharmacokinetics of Ketamine in Infants and Children
The Pk of IV Ketamine in Children With Heart Disease
Primary: Total Clearance and Intercompartmental Clearance — 60.0; 70.8 L/h/70kg
N/A N=70 Pharmacogenomic Testing to Personalize Supportive Oncology
Cancer · Depression · Pain
Primary: Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results — 9 Participants
N/A N=843 Personalized Health Assessment Related to Medications (Project PHARM)
Feedback, Psychological · Clinical Trial · Substance Abuse
Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03
N/A N=531 Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Gastrointestinal Cancer
Primary: Feasibility: Number and Percentage of Participants Who Had Their Pharmacogenetic Tests Returned Prior to Initial Dose — 130; 95 Participants
Phase 1 N=7 Pharmacodynamic Evaluation of Intranasal Nalmefene
Pharmacodynamic
Primary: Change in Minute Ventilation — 3.432; 5.744 L/min — p=<0.0009
Phase 2 N=66 Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
Healthy Volunteers · Brain Lesion
Primary: Pharmacokinetic (PK) Parameter Cmax — 248.7; 524.5; 698.7; 992.0 µg/mL
Phase 3 N=41 The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease
Cardiac Transplant · Patent Ductus Arterious · Atrial Septal Defect
Primary: Changes in Hemodynamic Variables Recorded During Administration of Sevoflurane + Dexmedetomidine. — -0.14; -0.16; -0.21; 0.15 percentage of change from baseline — p=0.05
N/A N=551 Pharmacological Management of Delirium
Delirium · Cognitive Impairment
Primary: Days Free of Delirium and Coma — 4; 5; 4; 5 days
Phase 1 N=26 Behavioral Pharmacology of Cannabis and Nicotine
Cannabis · Nicotine
Primary: Amount of Nicotine (mL of Smoke/Vapor) Inhaled — 0; 489.0; 1814.0; 1401.0 Volume in mL
N/A N=75 Pharmacogenomic Testing in Primary Care
Antidepressants Causing Adverse Effects in Therapeutic Use
Primary: Count of Participants Prescribed Antidepressant Medication — 5; 8; 5; 8 Participants
N/A N=179 Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care
Depression
Primary: Adherence to Antidepressant Medication — 78.4; 61.9; 60.1; 40.2 percentage of adherence patients
Early Phase 1 N=29 Neurophysiological and Acute Pharmacological Studies in FXS Patients
Fragile X Syndrome
Primary: Change in EEG Relative Gamma Power — 0.0024; -0.0077; -0.0039; 0.0019 percent of power in gamma frequencies
Phase 3 N=193 Individualized Obesity Pharmacotherapy
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
Phase 1 N=35 Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
Healthy
Primary: Adverse Events — 0; 0 participants
N/A N=48 Nalox-Comm: Naloxone Communication Training for Pharmacists
Naloxone
Primary: Change in Naloxone Dispensing Rate Over a 6-month Period — .0073; .0041 number of naloxone products dispensed — p=0.473
Phase 1 N=33 Behavioral Pharmacology of THC and Alpha-pinene
THC · Alpha-pinene
Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Phase 1 N=9 Pharmacokinetic Study of Vivitrol in Healthy Participants
Opioid-use Disorder
Primary: Median Cmax of Naltrexone (After 1st Dose) — 14.10 ng/mL
Phase 1 N=32 Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)
Healthy Volunteers
Primary: Nefopam and Paracetamol Pharmacokinetic Profiles in Each Arms After Single Dose — 101.808; 114.957; NA; 118.528 ng/mL